$DFTX

Barrow Robert (Chief Executive Officer) sold 31,550 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($1.15M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Sullivan Mark (Chief Legal Officer) sold 14,051 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.51M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Definium Therapeutics (DFTX) officer Mark Sullivan proposed selling 14,051 shares, valued at $516,093, on September 25, 2026. The shares are restricted stock vesting under a registered plan. Previously, 13,008 shares were sold on June 25, 2026, for $548,027. Morgan Stanley Smith Barney LLC is the broker.

Definium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.

Definium Therapeutics (DFTX) director Carol A. Vallone exercised stock options on September 18, 2026, acquiring 1,086 shares at $35.52 each. Post-transaction, she holds 22,296 shares directly. The exercised option position is now zero.

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

Definium Therapeutics (DFTX) granted stock options to three new non-executive employees, totaling 56,650 shares. The options, priced at the closing share price on the grant date, will vest over four years. The company's Compensation Committee approved the awards, aligning with Nasdaq rules. This reflects Definium's focus on attracting talent for its late-stage clinical pipeline.